Cell Therapeutics to Join Russell 3000® and Russell Global Indexes

      Cell Therapeutics to Join Russell 3000® and Russell Global Indexes

PR Newswire

SEATTLE, June 17, 2013

SEATTLE, June 17, 2013 /PRNewswire/ --Cell Therapeutics, Inc. ("CTI")
(NASDAQ: CTIC and MTA: CTIC) announced today that it is set to join the
broad-market Russell 3000® and Russell Global Indexes when Russell Investments
reconstitutes its comprehensive set of U.S. and global equity indexes on June
28, 2013, according to a preliminary list of additions posted on June 14,
2013and available at www.russell.com/indexes. Annual reconstitution of
Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of
May, ranking them by total market capitalization. Membership in the Russell
3000® Index, which remains in place for one year, means automatic inclusion in
the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as
the appropriate growth and value style indexes. Membership in the Russell
Global Index, which remains in place for one year, means automatic inclusion
in the appropriate large-cap, small-cap, all-cap indexes as well as the
applicable style, sector and country indexes. Russell determines membership
for its equity indexes primarily by objective, market capitalization rankings
and style attributes.

Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. Approximately$4.1 trillionin assets are benchmarked
to the Russell Indexes.

About Russell Investments

Russell Investments (Russell) is a global asset manager and one of only a few
firms that offers actively managed multi-asset portfolios and services that
include advice, investments and implementation. Russell stands with
institutional investors, financial advisors and individuals working with their
advisors ─ using the firm's core capabilities that extend across capital
market insights, manager research, portfolio construction, portfolio
implementation and indexes to help each achieve their desired investment

Russell has more than $173 billion in assets under management (as of
3/31/2013) and works with over 2,500 institutional clients, independent
distribution partners and individual investors globally. As a consultant to
some of the largest pools of capital in the world, Russell has $2.6 trillion
in assets under advisement (as of 12/31/2012). It has four decades of
experience researching and selecting investment managers and meets annually
with more than 2,200 managers around the world. Russell traded more than $1.4
trillion in 2012 through its implementation services business.

AboutCell Therapeutics, Inc.

CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the
development and commercialization of an integrated portfolio of oncology
products aimed at making cancer more treatable. CTI is headquartered
inSeattle, WA.For additional information and to sign up for email alerts and
get RSS feeds, please visitwww.CellTherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements that involve a number
of risks and uncertainties, the outcome of which could materially and/or
adversely affect actual future results and the trading price of our
securities. Specifically, the risks and uncertainties include risks associated
with preclinical and clinical developments in the biopharmaceutical industry
in general and CTI in particular, including determinations by regulatory,
patent and administrative governmental authorities, competitive factors,
technological developments, costs of developing products; CTI's ability to
continue to raise capital as needed to fund its operations;the impact of
CTI's inclusion in the Russell 3000®Index and/or the Russell Global Index;
the impact of a determination by Russell Investments not to include CTI in the
Russell 3000®Index and/or the Russell Global Index; even if CTI is included
in the Russell 3000®Index and/or the Russell Global Index, there is no
guarantee that CTI will continue to be included; and the risk factors listed
or described from time to time in CTI's filings with the Securities and
Exchange Commission including, without limitation, CTI's most recent filings
on Forms 10-K, 10-Q, and 8-K. Except as may be required by law, CTI does not
intend to update or alter its forward-looking statements whether as a result
of new information, future events, or otherwise

CTI Media and Investor Contacts:
Monique Greer
+1 206.272.4343

Ed Bell
+1 206.282.7100

In Europe
CTI Life Sciences Limited, Milan Branch
Laura Villa
E: CTI_EUInvestors@CTI-Lifesciences.com
T: +39 02 89659700

SOURCE Cell Therapeutics, Inc.

Website: http://www.celltherapeutics.com
Press spacebar to pause and continue. Press esc to stop.